雷迪帕韋/索磷布韋 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "雷迪帕韋/索磷布韋" in Chinese language version.

refsWebsite

Global rank Chinese rank

20web.archive.org

1^st place

13nih.gov

4^th place

5^th place

10doi.org

2^nd place

23^rd place

3tga.gov.au

3,984^th place

1,603^rd place

3gilead.com

low place

2drugs.com

399^th place

208^th place

2europa.eu

68^th place

209^th place

2handle.net

102^nd place

492^nd place

2natap.org

low place

1medicines.org.uk

3,823^rd place

3,456^th place

1semanticscholar.org

11^th place

332^nd place

1archive.org

6^th place

4^th place

1worldcat.org

5^th place

12^th place

1fda.gov

447^th place

581^st place

1canada.ca

1,712^th place

3,316^th place

1businesswire.com

615^th place

1,091^st place

1harvard.edu

18^th place

57^th place

1drugbank.ca

4,294^th place

8,905^th place

1kumc.edu

low place

archive.org

World Health Organization. The selection and use of essential medicines. Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. 2015: 69–70. ISBN 9789241209946. ISSN 0512-3054. hdl:10665/189763 . WHO technical report series;994.

businesswire.com

Health Canada Issues Notice of Compliance for Gilead's Harvoni (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C (新闻稿). Gilead Sciences, Inc. 2014-10-16 [2020-08-29]. （原始内容存档于2024-01-12） –通过Business Wire.

canada.ca

health-products.canada.ca

Notice of Compliance (NOC) online query. 2010-08-25 [2024-02-01]. （原始内容存档于2022-05-07）.

doi.org

Keating GM. Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C. Drugs. April 2015, 75 (6): 675–685. PMID 25837989. S2CID 31943736. doi:10.1007/s40265-015-0381-2.
Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. January 2015, 61 (1): 77–87. PMC 4303918 . PMID 25069599. doi:10.1002/hep.27259.
Issur M, Götte M. Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding. Viruses. November 2014, 6 (11): 4227–4241. PMC 4246218 . PMID 25384189. doi:10.3390/v6114227 .
Gao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Current Opinion in Virology. October 2013, 3 (5): 514–520. PMID 23896281. doi:10.1016/j.coviro.2013.06.014.
Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best Practice & Research. Clinical Gastroenterology. August 2012, 26 (4): 487–503. PMID 23199507. doi:10.1016/j.bpg.2012.09.011.
Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proceedings of the National Academy of Sciences of the United States of America. August 2001, 98 (17): 9599–9604. Bibcode:2001PNAS...98.9599G. PMC 55498 . PMID 11481452. doi:10.1073/pnas.171311298 .
Lin MV, Chung R. Recent FDA approval of sofosbuvir and simeprevir. Implications for current HCV treatment. Clinical Liver Disease. March 2014, 3 (3): 65–68. PMC 6448702 . PMID 30992888. doi:10.1002/cld.332.
Pawlotsky JM. NS5A inhibitors in the treatment of hepatitis C. Journal of Hepatology. August 2013, 59 (2): 375–382. PMID 23567084. doi:10.1016/j.jhep.2013.03.030 .
Cada DJ, Baker DE, Bindler RJ. Ledipasvir/Sofosbuvir. Hospital Pharmacy. March 2015, 50 (3): 224–234. PMC 4567193 . PMID 26405313. doi:10.1310/hpj5003-224.
Elkady EF, Aboelwafa AA. A Rapid and Optimized LC-MS/MS Method for the Simultaneous Extraction and Determination of Sofosbuvir and Ledipasvir in Human Plasma. Journal of AOAC International. September 2016, 99 (5): 1252–1259. PMID 27480956. doi:10.5740/jaoacint.16-0021.

drugbank.ca

Sofosbuvir. www.drugbank.ca. [2018-03-23]. （原始内容存档于2018-03-24）.

drugs.com

Ledipasvir / sofosbuvir (Harvoni) Use During Pregnancy. Drugs.com. 2019-10-28 [2020-03-17]. （原始内容存档于2020-03-17）.
Ledipasvir and Sofosbuvir. The American Society of Health-System Pharmacists. [2016-12-08]. （原始内容存档于2016-12-25）.

europa.eu

ema.europa.eu

Harvoni EPAR. European Medicines Agency (EMA). 2018-09-17 [2020-08-29]. （原始内容存档于2023-11-05）.
Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free). European Medicines Agency (EMA). 2018 -09-17 [2020-02-04]. （原始内容存档于2020-02-03）. 请检查|date=中的日期值 (帮助)

fda.gov

accessdata.fda.gov

Drug Approval Package:Harvoni (ledipasvir and sofosbuvir) Tablets NDA 205834. U.S. Food and Drug Administration (FDA). 2014-11-03 [2020-08-29]. （原始内容存档于2023-11-05）.
APPLICATION NUMBER: 205834Orig1s000 (PDF) (Summary Review). Center for Drug Evaluation and Research. [2024-02-01]. （原始内容存档 (PDF)于2022-12-08）.

gilead.com

Harvoni Presribing Information (PDF). Gilead Sciences. March 2020 [2018-02-21]. （原始内容存档 (PDF)于2018-02-22）.
Gilead Sciences Announces Third Quarter 2015 Financial Results. Gilead Sciences. 2015-10-27 [2024-01-12]. （原始内容存档于2023-09-26）.
Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results. Gilead Sciences. 2023-02-02 [2024-01-12]. （原始内容存档于2024-01-21）.

handle.net

hdl.handle.net

World Health Organization. The selection and use of essential medicines. Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. 2015: 69–70. ISBN 9789241209946. ISSN 0512-3054. hdl:10665/189763 . WHO technical report series;994.
World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

harvard.edu

ui.adsabs.harvard.edu

Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proceedings of the National Academy of Sciences of the United States of America. August 2001, 98 (17): 9599–9604. Bibcode:2001PNAS...98.9599G. PMC 55498 . PMID 11481452. doi:10.1073/pnas.171311298 .

kumc.edu

Pharmacology: Basic Pharmacology, ANS, Endocrine. www.kumc.edu. [2018-03-23]. （原始内容存档于2018-01-15）.

medicines.org.uk

Harvoni 90 mg/400 mg film-coated tablets - Summary of Product Characteristics. UK Electronic Medicines Compendium. December 2016 [2017-02-04]. （原始内容存档于2016-10-27）.

natap.org

Drug Interactions Between Direct-Acting anti-HCV Antivirals Sofosbuvir and Ledipasvir and HIV Antiretrovirals. www.natap.org. [2018-02-22]. （原始内容存档于2018-03-01）.
Impact of Food and Antacids on Levels of Ledipasvir and Sofosbuvir. www.natap.org. [2018-02-22]. （原始内容存档于2017-01-31）.

nih.gov

ncbi.nlm.nih.gov

Keating GM. Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C. Drugs. April 2015, 75 (6): 675–685. PMID 25837989. S2CID 31943736. doi:10.1007/s40265-015-0381-2.
Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. January 2015, 61 (1): 77–87. PMC 4303918 . PMID 25069599. doi:10.1002/hep.27259.
Holkira (Ombitasvir/Paritaprevir/ Ritonavir with Dasabuvir) and Harvoni (Ledipasvir/Sofosbuvir) for Chronic Hepatitis C: A Review of the Clinical Evidence. Rapid Response Service (Canadian Agency for Drugs and Technologies in Health). 2015-01-16. PMID 25674658. （原始内容存档于2017-11-05）.
Issur M, Götte M. Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding. Viruses. November 2014, 6 (11): 4227–4241. PMC 4246218 . PMID 25384189. doi:10.3390/v6114227 .
Gritsenko D, Hughes G. Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection. P & T. April 2015, 40 (4): 256–276. PMC 4378517 . PMID 25859119.
Gao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Current Opinion in Virology. October 2013, 3 (5): 514–520. PMID 23896281. doi:10.1016/j.coviro.2013.06.014.
Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best Practice & Research. Clinical Gastroenterology. August 2012, 26 (4): 487–503. PMID 23199507. doi:10.1016/j.bpg.2012.09.011.
Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proceedings of the National Academy of Sciences of the United States of America. August 2001, 98 (17): 9599–9604. Bibcode:2001PNAS...98.9599G. PMC 55498 . PMID 11481452. doi:10.1073/pnas.171311298 .
Lin MV, Chung R. Recent FDA approval of sofosbuvir and simeprevir. Implications for current HCV treatment. Clinical Liver Disease. March 2014, 3 (3): 65–68. PMC 6448702 . PMID 30992888. doi:10.1002/cld.332.
Pawlotsky JM. NS5A inhibitors in the treatment of hepatitis C. Journal of Hepatology. August 2013, 59 (2): 375–382. PMID 23567084. doi:10.1016/j.jhep.2013.03.030 .
Cada DJ, Baker DE, Bindler RJ. Ledipasvir/Sofosbuvir. Hospital Pharmacy. March 2015, 50 (3): 224–234. PMC 4567193 . PMID 26405313. doi:10.1310/hpj5003-224.
Elkady EF, Aboelwafa AA. A Rapid and Optimized LC-MS/MS Method for the Simultaneous Extraction and Determination of Sofosbuvir and Ledipasvir in Human Plasma. Journal of AOAC International. September 2016, 99 (5): 1252–1259. PMID 27480956. doi:10.5740/jaoacint.16-0021.

dailymed.nlm.nih.gov

Harvoni- ledipasvir and sofosbuvir tablet, film coated Harvoni- ledipasvir and sofosbuvir tablet, film coated Harvoni- ledipasvir and sofosbuvir pellet. DailyMed. 2020-03-16 [2020-08-29]. （原始内容存档于2023-04-17）.

semanticscholar.org

api.semanticscholar.org

Keating GM. Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C. Drugs. April 2015, 75 (6): 675–685. PMID 25837989. S2CID 31943736. doi:10.1007/s40265-015-0381-2.

tga.gov.au

AusPAR: Ledipasvir / Sofosbuvir. Therapeutic Goods Administration (TGA). 2015-10-29 [2020-08-29]. （原始内容存档于2022-05-07）.
AusPAR: Sofosbuvir / Ledipasvir. Therapeutic Goods Administration (TGA). 2017-11-16 [2020-08-29]. （原始内容存档于2022-05-07）.
Prescription medicines: registration of new chemical entities in Australia, 2015. Therapeutic Goods Administration (TGA). 2022-06-21 [2023-04-10]. （原始内容存档于2023-04-10）.

web.archive.org

Ledipasvir / sofosbuvir (Harvoni) Use During Pregnancy. Drugs.com. 2019-10-28 [2020-03-17]. （原始内容存档于2020-03-17）.
AusPAR: Ledipasvir / Sofosbuvir. Therapeutic Goods Administration (TGA). 2015-10-29 [2020-08-29]. （原始内容存档于2022-05-07）.
AusPAR: Sofosbuvir / Ledipasvir. Therapeutic Goods Administration (TGA). 2017-11-16 [2020-08-29]. （原始内容存档于2022-05-07）.
Prescription medicines: registration of new chemical entities in Australia, 2015. Therapeutic Goods Administration (TGA). 2022-06-21 [2023-04-10]. （原始内容存档于2023-04-10）.
Harvoni 90 mg/400 mg film-coated tablets - Summary of Product Characteristics. UK Electronic Medicines Compendium. December 2016 [2017-02-04]. （原始内容存档于2016-10-27）.
Harvoni- ledipasvir and sofosbuvir tablet, film coated Harvoni- ledipasvir and sofosbuvir tablet, film coated Harvoni- ledipasvir and sofosbuvir pellet. DailyMed. 2020-03-16 [2020-08-29]. （原始内容存档于2023-04-17）.
Harvoni EPAR. European Medicines Agency (EMA). 2018-09-17 [2020-08-29]. （原始内容存档于2023-11-05）.
Ledipasvir and Sofosbuvir. The American Society of Health-System Pharmacists. [2016-12-08]. （原始内容存档于2016-12-25）.
Drug Approval Package:Harvoni (ledipasvir and sofosbuvir) Tablets NDA 205834. U.S. Food and Drug Administration (FDA). 2014-11-03 [2020-08-29]. （原始内容存档于2023-11-05）.
APPLICATION NUMBER: 205834Orig1s000 (PDF) (Summary Review). Center for Drug Evaluation and Research. [2024-02-01]. （原始内容存档 (PDF)于2022-12-08）.
Notice of Compliance (NOC) online query. 2010-08-25 [2024-02-01]. （原始内容存档于2022-05-07）.
Health Canada Issues Notice of Compliance for Gilead's Harvoni (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C (新闻稿). Gilead Sciences, Inc. 2014-10-16 [2020-08-29]. （原始内容存档于2024-01-12） –通过Business Wire.
Holkira (Ombitasvir/Paritaprevir/ Ritonavir with Dasabuvir) and Harvoni (Ledipasvir/Sofosbuvir) for Chronic Hepatitis C: A Review of the Clinical Evidence. Rapid Response Service (Canadian Agency for Drugs and Technologies in Health). 2015-01-16. PMID 25674658. （原始内容存档于2017-11-05）.
Harvoni Presribing Information (PDF). Gilead Sciences. March 2020 [2018-02-21]. （原始内容存档 (PDF)于2018-02-22）.
Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free). European Medicines Agency (EMA). 2018 -09-17 [2020-02-04]. （原始内容存档于2020-02-03）. 请检查|date=中的日期值 (帮助)
Drug Interactions Between Direct-Acting anti-HCV Antivirals Sofosbuvir and Ledipasvir and HIV Antiretrovirals. www.natap.org. [2018-02-22]. （原始内容存档于2018-03-01）.
Impact of Food and Antacids on Levels of Ledipasvir and Sofosbuvir. www.natap.org. [2018-02-22]. （原始内容存档于2017-01-31）.
Sofosbuvir. www.drugbank.ca. [2018-03-23]. （原始内容存档于2018-03-24）.
Pharmacology: Basic Pharmacology, ANS, Endocrine. www.kumc.edu. [2018-03-23]. （原始内容存档于2018-01-15）.
Gilead Sciences Announces Third Quarter 2015 Financial Results. Gilead Sciences. 2015-10-27 [2024-01-12]. （原始内容存档于2023-09-26）.
Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results. Gilead Sciences. 2023-02-02 [2024-01-12]. （原始内容存档于2024-01-21）.

worldcat.org

World Health Organization. The selection and use of essential medicines. Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. 2015: 69–70. ISBN 9789241209946. ISSN 0512-3054. hdl:10665/189763 . WHO technical report series;994.